Jasper Therapeutics price target lowered to $8 from $21 at Oppenheimer

Oppenheimer analyst Jay Olson lowered the firm’s price target on Jasper Therapeutics to $8 from $21 and keeps an Outperform rating on the shares following quarterly results. The analyst notes the company continues to make progress on JSP191 across multiple opportunities, including recently reported promising data in the first two Fanconi Anemia patients. A registrational study in AML and MDS is on track for Q1 2023 initiation, Olson adds.